Prognostic Determinants in Acute Paracetamol Toxicity: Integrating Clinical Features and Biomarkers for Outcome Prediction

Nada Mohamed Mohamed Abdelhady, Manar Ali Elsayed, Wafaa Ibrahim Soliman, Omaima Ibrahim Abdel Hamid

Forensic Medicine and Clinical Toxicology Department, Faculty of Medicine, Zagazig University
Corresponding Author: Nada Mohamed Mohamed Abdelhady

Received: 28 October 2024, **Accepted:** 17 November 2024, **Published:** 20 November 2024

Abstract

Background: Acute paracetamol (acetaminophen) toxicity remains a leading cause of drug-induced acute liver failure worldwide. Although early administration of the antidote, N-acetylcysteine (NAC), markedly improves prognosis, the outcome prediction is still challenging in several practical scenarios: uncertain time of ingestion, delayed presentation, staggered or repeated supratherapeutic dosing, co-ingestions, and patients with evolving multiorgan dysfunction. Traditional risk assessment commonly relies on exposure history, serum paracetamol concentration, and routine hepatic biomarkers. However, many patients who later deteriorate may initially have modest abnormalities, while others exhibit marked biochemical derangements yet recover with appropriate supportive care. This clinical variability creates a need for integrated prognostic approaches that combine bedside clinical profile with dynamic laboratory signals that reflect both injury severity and systemic consequences.

Aim: This review synthesizes clinical determinants and laboratory biomarkers used to predict outcomes in acute paracetamol toxicity, emphasizing how early clinical findings and serial laboratory investigations can support risk stratification, escalation of care, and timely referral to specialized liver centers. We focus on practical parameters (vital signs, mental status, hemodynamics, acid–base status), conventional laboratory markers (aminotransferases, bilirubin, coagulation indices/INR, lactate, glucose, creatinine and electrolytes), and selected emerging biomarkers reflecting hepatocellular death, oxidative stress, and inflammatory activation (glutathione serum transferase (GST), reduced Glutathione level (GSH), malondialdehyde (MDA)). We also discuss how prognostic frameworks may be applied across different poisoning patterns and healthcare contexts, and how biomarker-informed assessment can complement established management pathways.

Conclusion: Outcome prediction in acute paracetamol toxicity should be **multidimensional and time-sensitive**—integrating clinical phenotype, organ-support requirements, and **serial** laboratory trends rather than relying on single time-point thresholds. Early recognition of high-risk profiles—particularly evolving worsening metabolic acidosis, encephalopathy, hypoglycemia, rising INR and renal dysfunction—can identify patients at risk of progression to acute liver failure and death/transplant. Combining conventional tests with biomarker-informed stratification offers a pathway toward earlier outcome prediction, more efficient use of critical care and extracorporeal support, and improved patient-centered outcomes.

Keywords: *Paracetamol; acetaminophen; overdose; acute liver injury; acute liver failure; prognosis; risk stratification; biomarkers; INR; hypoglycemia; renal injury; N-acetylcysteine; clinical toxicology.*

Introduction

Acute paracetamol (acetaminophen) poisoning represents one of the most common causes of toxicological hospital admission. Despite its widespread therapeutic use and favorable safety profile at recommended doses, paracetamol overdose is a leading contributor to drug-induced acute liver injury and acute liver failure worldwide, particularly in intentional self-poisoning and delayed presentation scenarios. Epidemiological analyses demonstrate persistent incidence across different regions and age groups, with significant healthcare burden related to emergency department visits, intensive care utilization, and liver transplantation requirements [1,2]. Contemporary reviews also emphasize that acetaminophen-induced hepatotoxicity remains the paradigm model for studying mechanisms of drug-induced liver injury [3].

The pathophysiology of acute paracetamol toxicity is well characterized and underpins prognostic evaluation. At toxic doses, excessive formation of the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) leads to glutathione depletion, mitochondrial dysfunction, oxidative stress, and hepatocellular necrosis. Sterile inflammation and innate immune activation further amplify tissue injury, particularly in delayed presentations [4,5]. This mechanistic understanding explains why certain laboratory abnormalities—such as rising aminotransferases, worsening coagulopathy, metabolic acidosis, and hyperlactatemia—correlate with severity and clinical outcomes. It also provides a biological rationale for integrating biomarkers reflecting hepatocyte death and systemic metabolic stress into prognostic models [6].

Although early administration of N-acetylcysteine significantly reduces morbidity and mortality, outcome prediction remains challenging in real-world practice. Patients may present with uncertain timing of ingestion, staggered overdose patterns, co-ingestants, or delayed referral after the onset of hepatic injury. Updated management guidelines highlight the importance of risk stratification but also acknowledge limitations in relying solely on serum paracetamol concentration or single laboratory thresholds, particularly outside clearly defined acute ingestion windows [7,8]. Observational studies have shown that progression to acute liver failure may occur despite apparently reassuring early laboratory values, whereas some patients with marked enzyme elevations recover fully with supportive therapy [9].

From a clinical toxicology standpoint, prognosis should be considered multidimensional and dynamic. Clinical features such as altered mental status, hemodynamic instability, hypoglycemia, and metabolic acidosis often signal systemic deterioration and may precede or accompany worsening hepatic function. Laboratory indicators including aminotransferases, bilirubin, international normalized ratio (INR), lactate, creatinine, and electrolyte disturbances provide objective measures of organ injury and perfusion status. Furthermore, emerging mechanistic biomarkers have been proposed to enhance early prediction of severe outcomes beyond conventional tests [10,11].

The aim of this review is to synthesize available evidence regarding clinical profile characteristics and laboratory biomarkers that predict outcomes in acute paracetamol toxicity, integrating traditional parameters with evolving mechanistic insights. The research gap addressed is the lack of a unified, clinically applicable framework that combines bedside assessment with serial laboratory trends to improve early identification of patients at risk for acute liver failure, transplantation, or death. By examining both established and emerging prognostic determinants, this review seeks to provide a structured toxicological perspective to guide risk stratification and escalation of care.

Pathophysiology of Acute Paracetamol Toxicity and Its Prognostic Implications

Paracetamol-induced hepatotoxicity is a dose-dependent process driven primarily by metabolic bioactivation. Under therapeutic conditions, most paracetamol undergoes glucuronidation and sulfation, while a small fraction is oxidized by cytochrome P450 enzymes—particularly CYP2E1—to form the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI). At toxic doses, conjugation pathways become saturated, leading to excessive NAPQI formation and depletion of intracellular glutathione stores. When glutathione is exhausted, NAPQI binds to cellular proteins, initiating hepatocellular injury. This metabolic framework is fundamental for understanding why timing of presentation and antidote

administration critically influence prognosis [12,13].

Mitochondrial dysfunction is a central feature of severe toxicity. NAPQI-induced protein adduct formation within mitochondria promotes oxidative stress, impaired ATP synthesis, and activation of cell death pathways. Experimental and translational studies have demonstrated that oxidative stress and lipid peroxidation amplify hepatocyte necrosis and contribute to systemic inflammatory responses. The degree of mitochondrial impairment correlates with the severity of liver injury, explaining why biomarkers reflecting oxidative stress and hepatocyte death may have prognostic value beyond routine liver enzymes [4,14].

Sterile inflammation further modulates the progression of liver injury. Damage-associated molecular patterns released from necrotic hepatocytes activate innate immune signaling pathways, including cytokine and chemokine cascades, which may worsen hepatic and extrahepatic organ dysfunction. The balance between injury amplification and regenerative signaling partly determines outcome. Evidence from experimental models highlights that pathways involved in liver regeneration, including epidermal growth factor receptor signaling and autophagic flux, influence recovery after overdose, suggesting that dynamic biological responses—not just initial injury magnitude—shape prognosis [5,15,16,17].

Extrahepatic manifestations are increasingly recognized in acute paracetamol toxicity. Renal dysfunction may occur independently or in parallel with hepatic injury, and pulmonary and cardiovascular effects have been described in severe cases. These systemic complications can significantly worsen outcomes and are often reflected in laboratory abnormalities such as rising creatinine, metabolic acidosis, and elevated lactate. Therefore, prognostic assessment must extend beyond hepatic enzymes to encompass markers of global organ function [18,19].

Importantly, the temporal evolution of biochemical changes reflects underlying pathophysiology. Aminotransferases typically rise after hepatocellular injury has occurred, while coagulation abnormalities and metabolic disturbances signal impaired synthetic and metabolic capacity. Studies examining the timing of aminotransferase elevation demonstrate that enzyme rise may lag behind the initial toxic insult, reinforcing the importance of serial testing rather than single time-point interpretation. Consequently, integrating mechanistic understanding with dynamic laboratory trends provides a rational foundation for outcome prediction in acute paracetamol toxicity [20].

Clinical Profile as an Early Determinant of Outcome

The initial clinical presentation in acute paracetamol toxicity is often nonspecific, particularly within the first 24 hours, where nausea, vomiting, malaise, and diaphoresis predominate. However, the absence of severe early symptoms does not exclude evolving hepatotoxicity. Epidemiological studies demonstrate that many patients who later develop significant liver injury initially appear clinically stable, especially in single acute ingestions. Therefore, early bedside evaluation must be interpreted cautiously and integrated with risk assessment tools and laboratory follow-up rather than relied upon in isolation [1,2].

Intentional self-poisoning remains the predominant context of acute overdose in many regions, with variations in demographic patterns, psychiatric comorbidity, and co-ingestants influencing presentation and outcomes. Population-based and registry data indicate that younger individuals frequently present after deliberate ingestion, whereas older adults may exhibit more severe outcomes due to comorbidities or delayed presentation. Patterns such as staggered ingestion and uncertain timing complicate interpretation of serum drug levels and increase the risk of delayed hepatotoxicity [2,21,22].

The timing of presentation relative to ingestion is a critical prognostic determinant. Early presenters treated promptly with N-acetylcysteine generally have favorable outcomes, while delayed presentation beyond 8–24 hours increases the risk of hepatic necrosis and acute liver failure. Clinical reviews emphasize that delayed initiation of antidotal therapy is consistently associated with worse biochemical progression and higher rates of transplantation or death, particularly in patients presenting after the onset of abdominal pain or systemic symptoms [8,23].

Altered mental status is a pivotal clinical marker of severity. The development of hepatic encephalopathy signifies progression to acute liver failure and is strongly associated with poor prognosis. Assessment tools such as the Glasgow Coma Scale provide structured evaluation of consciousness and facilitate

serial monitoring in critically ill patients. Deterioration in neurological status, particularly when accompanied by coagulopathy and metabolic acidosis, identifies patients requiring urgent referral to specialized liver units [24,25].

Hemodynamic instability, hypotension, and signs of systemic hypoperfusion also carry prognostic significance. Severe overdose may lead to vasodilation and cardiovascular compromise, sometimes independent of advanced hepatic failure. These systemic manifestations contribute to secondary organ injury and correlate with adverse outcomes. Recognition of shock states, persistent tachycardia, or need for vasopressor support should therefore prompt aggressive monitoring and escalation of care [26,27].

Importantly, certain symptoms traditionally considered markers of severity, such as abdominal pain, may not reliably predict the extent of hepatic injury. Recent clinical evaluations have demonstrated that the presence of abdominal pain alone does not correlate consistently with biochemical severity or ultimate outcome. This underscores the need to prioritize objective clinical and laboratory parameters over isolated subjective symptoms in prognostic assessment [28].

Together, these clinical features—timing of presentation, intent and pattern of ingestion, mental status changes, and hemodynamic stability—form the foundation of early risk stratification. However, because early symptoms may underestimate evolving injury, continuous reassessment and integration with laboratory biomarkers remain essential for accurate outcome prediction.

Conventional Laboratory Biomarkers in Outcome Prediction

Serum aminotransferases remain the cornerstone laboratory markers for detecting hepatocellular injury in acute paracetamol toxicity. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations reflect hepatocyte membrane disruption and cytosolic enzyme release. Standardized measurement methods established by the International Federation of Clinical Chemistry ensure analytical consistency across laboratories, supporting their widespread clinical application. In paracetamol overdose, aminotransferase levels may rise dramatically, often exceeding several thousand international units per liter in severe cases. However, the magnitude of elevation alone does not necessarily predict mortality, as some patients with very high transaminases recover with appropriate therapy [29,30].

The temporal pattern of aminotransferase elevation provides more prognostic insight than single absolute values. Studies examining the timing of enzyme rise demonstrate that AST and ALT typically begin increasing within 24 hours after significant ingestion, peaking between 48 and 72 hours. Persistently rising or secondarily increasing levels may indicate ongoing injury or delayed presentation. Conversely, a downward trend after peak elevation, particularly with stable coagulation parameters, generally signals hepatic recovery. Therefore, serial measurement rather than isolated testing is essential in prognostic evaluation [20].

Coagulation parameters, particularly the international normalized ratio (INR), serve as key indicators of hepatic synthetic function. Unlike aminotransferases, which reflect structural injury, INR elevation represents impaired synthesis of clotting factors and is closely linked to prognosis in acute liver failure. Progressive coagulopathy correlates with increased mortality risk and forms part of widely used prognostic frameworks in severe hepatotoxicity. Accurate laboratory determination of prothrombin time and INR is thus central to clinical decision-making and transplant referral considerations [31,32].

Serum bilirubin provides additional information regarding hepatic excretory function. Although hyperbilirubinemia may develop later than transaminase elevation in paracetamol toxicity, rising bilirubin levels in conjunction with worsening INR suggest substantial hepatic dysfunction. Laboratory methods for bilirubin quantification are well standardized, allowing reliable longitudinal assessment. The combination of elevated bilirubin and coagulopathy often marks transition from isolated hepatocellular injury to established acute liver failure [33].

Metabolic parameters, including blood glucose, are also important prognostic indicators. Hypoglycemia reflects impaired gluconeogenesis and depleted hepatic glycogen stores in advanced injury. Episodes of hypoglycemia have been associated with poor outcomes and may precede overt encephalopathy. Accurate laboratory determination of serum glucose is therefore critical in monitoring patients with

evolving toxicity, particularly in those presenting late or with altered mental status [34].

Renal function markers, especially serum creatinine, contribute significantly to risk stratification. Acute kidney injury may occur in severe paracetamol toxicity, either secondary to hepatic failure or as a direct toxic effect. Elevated creatinine levels are associated with worse prognosis and increased likelihood of multiorgan failure. Reliable enzymatic and Jaffé-based methods for creatinine measurement support its role as an accessible and practical biomarker in routine clinical settings [35,36].

Collectively, conventional laboratory biomarkers—aminotransferases, INR, bilirubin, glucose, and creatinine—form the core of prognostic evaluation in acute paracetamol toxicity. While each parameter provides valuable information independently, their combined interpretation over time offers the most accurate reflection of injury progression and clinical outcome.

Lactate, Acid–Base Status, and Metabolic Derangements

Metabolic acidosis is a critical indicator of severe paracetamol toxicity and frequently reflects advanced hepatic dysfunction or systemic hypoperfusion. Lactic acidosis may develop early in massive overdose due to mitochondrial impairment and reduced oxidative phosphorylation, even before overt hepatic necrosis becomes evident. As injury progresses, impaired hepatic clearance of lactate further exacerbates hyperlactatemia. Clinical analyses have demonstrated that elevated lactate levels correlate strongly with mortality and may outperform traditional criteria in predicting death or need for transplantation in certain patient cohorts [37,38].

Understanding the pathogenesis of lactic acidosis in paracetamol poisoning is essential for accurate interpretation. Mechanistically, mitochondrial oxidative stress induced by NAPQI disrupts cellular respiration, promoting anaerobic metabolism and lactate accumulation. Additionally, hypotension and systemic vasodilation may worsen tissue hypoxia, compounding metabolic derangements. Therefore, elevated lactate represents both hepatic metabolic failure and global circulatory compromise, making it a valuable integrative biomarker of severity [39].

Arterial blood gas analysis provides comprehensive information regarding acid–base balance, oxygenation, and carbon dioxide status. In critically ill patients, metabolic acidosis with low bicarbonate and elevated lactate should prompt urgent reassessment and escalation of care. Blood gas interpretation allows early identification of patients progressing toward acute liver failure and multiorgan dysfunction. Integration of arterial blood gas parameters with clinical findings enhances early detection of high-risk cases and supports timely transfer to intensive care or specialized liver units [40].

Hypoglycemia represents another significant metabolic complication in advanced toxicity. Severe hepatocellular injury impairs gluconeogenesis and glycogenolysis, predisposing patients to critically low glucose levels. Hypoglycemia has been associated with poor outcomes and may serve as an early marker of hepatic synthetic failure. Prompt recognition and correction are essential, but its presence should also trigger consideration of advanced hepatic dysfunction and possible transplant evaluation [38].

In some cases, metabolic disturbances may be atypical. Reports describe presentations with hyperglycemia, acidosis, and ketonuria in non-diabetic individuals following significant overdose, underscoring the complexity of metabolic responses in severe toxicity. These findings reinforce the importance of comprehensive metabolic assessment rather than reliance on a single parameter [41].

Overall, lactate levels, arterial blood gas findings, and glucose abnormalities provide dynamic insight into systemic consequences of paracetamol toxicity. When interpreted alongside hepatic and renal markers, these metabolic parameters significantly strengthen prognostic assessment and facilitate early identification of patients at risk for adverse outcomes.

Renal Dysfunction and Electrolyte Abnormalities as Prognostic Markers

Acute kidney injury is a clinically important complication of paracetamol toxicity and is consistently associated with worse outcomes, particularly when it develops alongside hepatic failure. Renal impairment may result from several mechanisms, including systemic hypoperfusion in critically ill patients, hepatorenal physiology in advanced liver failure, and direct nephrotoxic effects of reactive metabolites within renal tissue. Observational clinical reports highlight that renal injury can occasionally

occur even in the absence of severe hepatic impairment, reinforcing that prognosis should not be framed as liver-only in paracetamol poisoning [42].

Renal dysfunction contributes to outcome prediction in two ways: it is both a marker of systemic severity and a driver of complications. Rising serum creatinine and reduced urine output correlate with increased risk of multiorgan failure, prolonged intensive care admission, and mortality. Studies assessing predictors of kidney injury in acetaminophen poisoning identify delayed presentation, higher ingested doses, and concurrent hepatic dysfunction among the strongest clinical correlates. In settings where ingestion history is unreliable, early creatinine elevation can provide an objective signal that the patient is already on a complicated clinical trajectory [43].

Electrolyte disturbances frequently accompany renal injury and advanced hepatic dysfunction. Derangements in sodium, potassium, and bicarbonate may reflect vomiting-related losses, renal tubular dysfunction, or acid–base imbalance from lactic acidosis. Evaluation of serum electrolytes is therefore essential, not only for supportive management but also for recognizing progression toward systemic instability. Recent clinical evaluations of acute single overdoses have demonstrated measurable impacts on renal function and serum electrolytes, emphasizing their utility as routine monitoring parameters in prognostic assessment [44].

The interplay between renal dysfunction and hepatic injury is clinically significant because each can amplify the other. Worsening renal function may impair elimination of metabolites and complicate antidote dosing strategies, while hepatic failure can reduce renal perfusion and trigger inflammatory cascades that promote kidney injury. This bidirectional relationship strengthens the prognostic importance of combining creatinine and electrolyte monitoring with hepatic biomarkers, rather than interpreting them separately [3,45].

In summary, renal impairment and electrolyte abnormalities provide accessible and clinically meaningful indicators of adverse prognosis in acute paracetamol toxicity. Serial assessment of creatinine, urine output, and electrolyte trends complements hepatic and metabolic markers, supporting earlier recognition of patients at risk for multiorgan dysfunction, intensive care needs, and poor outcomes.

Prognostic Scores and Integrated Risk Stratification Frameworks

Prognostic assessment in acute paracetamol toxicity is most clinically useful when it is structured, reproducible, and capable of guiding escalation decisions such as intensive care admission, referral to liver centers, and transplant evaluation. Contemporary consensus and guideline-focused reviews emphasize that prognostication should integrate exposure pattern, time from ingestion, response to N-acetylcysteine, and objective organ dysfunction markers rather than relying on a single laboratory value. This approach reflects the reality that many high-risk presentations involve uncertain timing, staggered dosing, or delayed referral where drug concentration-based tools are less informative for outcome prediction [46,47].

The Poisoning Severity Score (PSS) was developed to provide standardized grading of acute poisoning severity across different toxic exposures, supporting consistent clinical documentation and research comparability. In paracetamol poisoning, the PSS conceptually aligns with a stepwise progression from mild early symptoms to severe systemic toxicity with hepatic failure and multiorgan dysfunction. However, clinical toxicology discussions highlight that while PSS can be valuable for standardized reporting, it may not always map precisely onto toxin-specific outcome pathways or provide adequate granularity for transplant-oriented decisions, particularly in rapidly evolving acetaminophen-induced acute liver failure [48,49].

In advanced paracetamol hepatotoxicity, transplant-oriented prognostic frameworks have traditionally relied heavily on markers of hepatic synthetic failure and systemic metabolic stress. Clinical evidence indicates that metabolic variables, especially lactic acidosis and hypoglycemia, can carry strong prognostic power and in some cohorts have outperformed traditional criteria for predicting death or transplant. These findings reinforce the concept that risk stratification improves when it incorporates both hepatic failure markers (such as INR) and systemic derangement markers (such as lactate and

glucose), reflecting whole-body physiology rather than liver injury alone [37,38].

Coagulation assessment remains central to prognostic scoring because it reflects loss of hepatic synthetic capacity and correlates with mortality risk in acute liver failure. Interpretation depends on reliable prothrombin time and INR measurement, and methodological clarity supports comparability across institutions. In practice, a worsening INR trajectory despite ongoing antidotal therapy and supportive care should be considered a high-risk signal, particularly when accompanied by renal dysfunction, acidosis, or mental status decline, even if aminotransferases have peaked or begun to fall [31,50].

A practical integrated framework in the emergency and critical care setting can be organized around three domains: clinical phenotype, metabolic stress, and organ failure progression. Clinical phenotype includes mental status changes and hemodynamic instability; metabolic stress includes lactate, acid–base status, and glucose; and organ failure progression includes INR trend, creatinine trajectory, and evolving encephalopathy. This multidomain approach is consistent with modern toxicology guidance that emphasizes serial reassessment and trajectory-based interpretation to identify patients who require early transfer for advanced liver support or transplantation pathways [46,39].

Finally, integrated prognostication must remain adaptive to healthcare context. Cohort studies from poison centers and regional systems demonstrate variability in presentation patterns, management pathways, and outcomes, meaning that rigid application of any single score may underperform without local validation. Embedding structured clinical assessment with serial laboratory trends offers a robust, transportable approach that can be applied across systems while still allowing refinement based on local population characteristics and resource availability [51,9].

Emerging and Mechanistic Biomarkers in Outcome Prediction

While conventional laboratory tests remain the backbone of prognostic assessment, increasing attention has focused on mechanistic biomarkers that reflect specific pathways of hepatocyte injury and cell death. Advances in understanding acetaminophen-induced liver injury have enabled identification of circulating markers that may rise earlier than traditional aminotransferases or provide more direct insight into the mode and severity of cellular injury. Translational research has highlighted that biomarkers linked to mitochondrial dysfunction, oxidative stress, and regulated necrosis may improve early risk stratification, particularly in patients presenting before peak transaminase elevation [6,3].

Glutathione S-transferase A1 (GSTA1) has been investigated as a sensitive marker of hepatocellular injury. Experimental and clinical data demonstrate that GSTA1 levels increase rapidly following acetaminophen-induced hepatocyte damage, reflecting early cytosolic enzyme release. Compared with conventional aminotransferases, GSTA1 may rise earlier in the course of injury and decline more rapidly with recovery, making it a potentially valuable dynamic biomarker. Studies evaluating GSTA1 in acute acetaminophen toxicity suggest its utility in identifying patients at risk of significant hepatotoxicity before overt clinical deterioration occurs [52,53].

Cytokeratin-18 (CK-18) fragments, particularly caspase-cleaved forms, have been proposed as indicators of hepatocyte death pathways. Elevated serum CK-18 levels have been associated with acute paracetamol-induced liver injury and may help distinguish between necrotic and apoptotic patterns of cell death. Early increases in CK-18 fragments have shown promise as predictors of subsequent severe hepatotoxicity, offering mechanistic insight beyond routine enzyme measurements [54].

Mechanistic biomarker panels incorporating microRNA signatures, high mobility group box-1 protein (HMGB1), and other damage-associated molecular patterns have also been explored. Prospective cohort investigations demonstrate that combinations of such biomarkers can enhance early risk stratification following overdose, particularly when integrated with clinical parameters. These biomarkers reflect sterile inflammatory activation and mitochondrial injury, reinforcing the concept that early systemic signals may precede overt synthetic liver failure [6].

Oxidative stress markers and lipid peroxidation products have additionally been studied in experimental and clinical contexts. Given that oxidative stress is central to acetaminophen hepatotoxicity, measurement of glutathione depletion and lipid peroxidation indices provides mechanistic correlation with severity. Laboratory assays assessing glutathione levels and thiobarbituric acid–reactive substances

have been utilized in research settings, although their routine clinical application remains limited. Nevertheless, their biological relevance underscores the importance of oxidative stress in determining progression and recovery [55,56].

Despite promising data, several limitations restrict widespread clinical adoption of emerging biomarkers. Many studies remain cohort-specific, and assay availability, standardization, and cost considerations limit real-world implementation. Furthermore, the incremental predictive value of novel markers must be demonstrated beyond established parameters such as INR, lactate, and creatinine before routine integration into practice. However, the trajectory of research suggests that combining mechanistic biomarkers with conventional laboratory tests may ultimately enable earlier and more precise outcome prediction in acute paracetamol toxicity [3,6].

Management-Related Determinants That Influence Outcome

Early initiation of N-acetylcysteine remains the most important modifiable determinant of outcome in acute paracetamol toxicity, because it replenishes glutathione stores and limits progression to hepatic necrosis when given promptly. Contemporary guidance and consensus statements emphasize that delays in antidote administration, uncertainty in ingestion timing, and complex exposure patterns (including staggered ingestion) are key contributors to preventable severe outcomes. Therefore, treatment decisions should prioritize timely antidote delivery and serial reassessment rather than waiting for late-stage biochemical confirmation in high-risk presentations [57,58].

The choice of acetylcysteine route and regimen can also influence clinical course, especially through adverse reactions, completion rates, and treatment interruptions. Comparative evidence evaluating oral versus intravenous acetylcysteine supports efficacy of both approaches, while highlighting practical differences in tolerability and logistics that can affect adherence and continuity of therapy in real-world care. Interruptions in antidote administration during a critical window may contribute to biochemical progression in selected patients, reinforcing the need for protocols that ensure uninterrupted delivery and management of adverse effects [59].

Massive paracetamol overdose represents a distinct prognostic category in which standard antidotal strategies may be insufficient. Observational studies of massive ingestion report higher rates of early metabolic acidosis, lactate elevation, altered mental status, and organ failure, with poorer overall outcomes compared with typical overdoses. These cases often require early critical care involvement and consideration of enhanced elimination or adjunctive therapies, particularly when there is evidence of severe metabolic derangement despite acetylcysteine therapy [60].

Extracorporeal treatments may affect outcome in selected severe cases, particularly when very high paracetamol concentrations coexist with profound acidosis or clinical instability. Hemodialysis can remove paracetamol and also impacts acetylcysteine kinetics, meaning that antidote dosing and monitoring must be adapted during extracorporeal therapy. Evidence describing massive overdose management with hemodialysis supports its role as a targeted intervention in extreme toxicity, where rapid toxin removal and correction of metabolic abnormalities may be life-saving [61].

Adjunctive pharmacologic strategies have gained interest for high-risk scenarios, especially fomepizole (4-methylpyrazole), which may reduce toxic metabolite formation by inhibiting cytochrome P450-mediated bioactivation. Scoping reviews describe growing clinical experience with fomepizole as an adjunct in severe or massive overdose, but also emphasize that evidence is still developing and should be applied within structured protocols and specialist consultation frameworks. From an outcome prediction perspective, the need for such adjuncts often signals a high-severity trajectory and should trigger intensified monitoring and early referral pathways [62,13].

For patients progressing to acute liver failure despite optimal antidotal therapy, advanced liver support and transplantation pathways become the major determinants of survival. Contemporary critical care literature describes liver assistive devices and extracorporeal liver support systems as bridging options in selected patients, while multicenter studies have evaluated molecular adsorbent recirculating system use in acute liver failure settings. Case-based experiences with early “liver dialysis” approaches also highlight the clinical priority of timely escalation and transfer to centers capable of advanced support

and transplant assessment when prognostic indicators worsen [63,64,65].

Conclusion

Acute paracetamol toxicity continues to represent a major cause of acute liver injury and acute liver failure, with outcome largely determined by early recognition, timely antidotal therapy, and accurate risk stratification. Prognosis cannot be reliably predicted using a single clinical or biochemical parameter. Instead, it requires integration of clinical presentation—particularly mental status changes, hemodynamic instability, and timing of ingestion—with serial laboratory trends. Conventional biomarkers such as aminotransferases, INR, bilirubin, lactate, glucose, and creatinine remain central to assessment, but their prognostic value lies primarily in their dynamic evolution rather than isolated values. Progressive coagulopathy, persistent metabolic acidosis, hyperlactatemia, hypoglycemia, and worsening renal dysfunction consistently identify patients at highest risk for acute liver failure, transplantation, or death.

A multidimensional and time-sensitive framework therefore offers the most reliable approach to outcome prediction. Integrating bedside clinical phenotype with metabolic indicators and organ failure markers enhances early identification of high-risk trajectories and supports timely escalation to intensive care or transplant referral. Emerging mechanistic biomarkers may further refine early detection of severe hepatocellular injury, although broader validation and accessibility are still needed. Ultimately, structured and repeated reassessment remains the cornerstone of prognostication in acute paracetamol toxicity, ensuring that management decisions are guided by evolving physiology rather than static thresholds.

References

1. Casey D, Geulayov G, Bale E, et al. Paracetamol self-poisoning: Epidemiological study of trends and patient characteristics from the multicentre study of self-harm in England. *J Affect Disord*. 2020;276:699–706.
2. Friðriksdóttir ÞA, Jónsdóttir F, Snook CP, Líndal H, Björnsson ES. Paracetamol poisoning: a population-based study from Iceland. *Scand J Gastroenterol*. 2021;56(7):832–839.
3. Jaeschke H, Ramachandran A. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. *Annu Rev Pathol*. 2024;19(1):453–478.
4. Jaeschke H, Ramachandran A. Oxidant stress and lipid peroxidation in acetaminophen hepatotoxicity. *Reactive Oxygen Species*. 2018;5(15):145–158.
5. Jaeschke H, Ramachandran A. Mechanisms and pathophysiological significance of sterile inflammation during acetaminophen hepatotoxicity. *Food Chem Toxicol*. 2020;138:111240.
6. Dear JW, Clarke JI, Francis B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: Results from two prospective cohort studies. *Lancet Gastroenterol Hepatol*. 2018;3(2):104–113.
7. Chiew AL, Reith D, Pomerleau A, et al. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. *Med J Aust*. 2020;212(4):175–183.
8. Dart RC, Mullins ME, Matoushek T, et al. Management of acetaminophen poisoning in the US and Canada: A consensus statement. *JAMA Netw Open*. 2023;6(8):e2327739.
9. Mehrpour O, Saeedi F, Hadianfar A, Mégarbane B, Hoyte C. Prognostic factors of acetaminophen exposure in the United States: An analysis of 39,000 patients. *Hum Exp Toxicol*. 2021;40(12 Suppl):S814–S825.
10. Yan M, Huo Y, Yin S, Hu H. Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions. *Redox Biol*. 2018;17:274–283.
11. Yoon E, Babar A, Choudhary M, Kutner M, Pyrsopoulos N. Acetaminophen-induced hepatotoxicity: A comprehensive update. *J Clin Transl Hepatol*. 2016;4(2):131–142.
12. McGill MR, Jaeschke H. Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. *Pharm Res*. 2013;30(9):2174–2187.
13. Mazaleuskaya LL, Sangkuhl K, Thorn CF, et al. PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. *Pharmacogenet Genomics*. 2015;25(8):416–426.
14. Ramachandran A, Jaeschke H. Mechanisms of acetaminophen hepatotoxicity and their translation to the human pathophysiology. *J Clin Transl Res*. 2017;3(Suppl 1):157–169.
15. Luo G, Huang L, Zhang Z. The molecular mechanisms of acetaminophen-induced hepatotoxicity and its potential therapeutic targets. *Exp Biol Med (Maywood)*. 2023;248(5):412–424.
16. Bhushan B, Chavan H, Borude P, et al. Dual role of epidermal growth factor receptor in liver injury and regeneration after acetaminophen overdose in mice. *Toxicol Sci*. 2017;155(2):363–378.

17. Kang KY, Shin JK, Lee SM. Pterostilbene protects against acetaminophen-induced liver injury by restoring impaired autophagic flux. *Food Chem Toxicol*. 2019;123:536–545.
18. Khan Z, Abumedian M, Ibekwe M, Musa K, Mlawa G. Acute renal impairment in patients due to paracetamol overdose in the absence of hepatic impairment. *Cureus*. 2021;13(12):e20727.
19. Dobrinskikh E, Al-Juboori SI, Zarate MA, et al. Pulmonary implications of acetaminophen exposures independent of hepatic toxicity. *Am J Physiol Lung Cell Mol Physiol*. 2021;321(5):L941–L953.
20. Green TJ, Sivilotti ML, Langmann C, et al. When do the aminotransferases rise after acute acetaminophen overdose? *Clin Toxicol (Phila)*. 2010;48(8):787–792.
21. Daly C, Griffin E, McMahon E, et al. Paracetamol-related intentional drug overdose among young people. *Soc Psychiatry Psychiatr Epidemiol*. 2021;56(5):773–781.
22. Castanares-Zapatero D, Dinant V, Ruggiano I, et al. Pattern of paracetamol poisoning: Influence on outcome and complications. *Toxics*. 2018;6(4):58.
23. Heard K. Acetaminophen poisoning: A case based approach. *J Acute Med*. 2018;8(3):77–85.
24. Mattei TA, Teasdale GM. The story of the development and adoption of the Glasgow Coma Scale. *World Neurosurg*. 2020;134:311–322.
25. Arshad MA, Bangash MN. Acute liver failure following paracetamol overdose. *J Intensive Care Soc*. 2022;23(2):244–251.
26. Van der Horst J, Manville RW, Hayes K, et al. Acetaminophen metabolites induce vasodilation and hypotension. *Arterioscler Thromb Vasc Biol*. 2020;40(5):1207–1219.
27. Ralapanawa U, Jayawickreme KP, Ekanayake EM, Dissanayake AM. A study on paracetamol cardiotoxicity. *BMC Pharmacol Toxicol*. 2016;17(1):30.
28. Wang C, Wong A. The presence of abdominal pain associated with acetaminophen overdose does not predict severity of liver injury. *Am J Emerg Med*. 2024;79:52–57.
29. Bergmeyer HU. IFCC method for alanine aminotransferase. *Clin Chim Acta*. 1980;105(1):147–154.
30. Bergmeyer HU, Horder M, Rey J. IFCC method for aspartate aminotransferase. *J Clin Chem Clin Biochem*. 1986;24(1):497–510.
31. Ignjatovic V. Prothrombin time/international normalized ratio. *Methods Mol Biol*. 2013;992:121–129.
32. Levine M, Stellpflug S, Pizon A, et al. Hypoglycemia and lactic acidosis outperform King's College criteria. *Clin Toxicol (Phila)*. 2018;56:1–4.
33. Wahlefeld AW, Herz G, Bernt E. Determination of total bilirubin in serum. *Scand J Clin Lab Invest*. 1972;29(Suppl 126).
34. Zhu A, Romero R, Petty HR. Enzymatic colorimetric assay for glucose-6-phosphate. *Anal Biochem*. 2011;419(2):266–270.
35. Masson P, Ohlsson P, Björkhem I. Combined enzymic-Jaffé method for creatinine determination. *Clin Chem*. 1981;27(1):18–21.
36. Jacobs DS, DeMott WR, Oxley DK. *Laboratory Test Handbook*. 5th ed. Lexi-Comp; 2001.
37. Shah AD, Wood DM, Dargan PI. Understanding lactic acidosis in paracetamol poisoning. *Br J Clin Pharmacol*. 2011;71(1):20–28.
38. Levine M, Stellpflug S, Pizon A, et al. Hypoglycemia and lactic acidosis outperform King's College criteria. *Clin Toxicol (Phila)*. 2018;56:1–4.
39. Jaeschke H, Ramachandran A. Oxidant stress and lipid peroxidation in acetaminophen hepatotoxicity. *Reactive Oxygen Species*. 2018;5(15):145–158.
40. Balzanelli MG, Distratis P, Lazzaro R, et al. Importance of arterial blood gas analysis. *Eur Rev Med Pharmacol Sci*. 2023;27(23):11653–11663.
41. Macfie C, Wall E, Ash S. Paracetamol overdose presenting with hyperglycaemia, acidosis and ketonuria. *Acute Med*. 2009;8(2):78–79.
42. Roshdi A, Hassan O, Ahmed M, Abd-EL Azeem A. Impact of acute single paracetamol overdose on renal functions. *Minia J Med Res*. 2024;35(2):72–79.
43. Akhoundi F, Rahimi M, Hosseini SM. Predictive factors for liver and kidney injury in acetaminophen poisoning. *Med J Armed Forces India*. 2025.
44. Roshdi A, Hassan O, Ahmed M, Abd-EL Azeem A. Evaluation of renal functions and serum electrolytes. *Minia J Med Res*. 2024;35(2):72–79.
45. Kumar S, Singla B, Singh AK, et al. Cytochrome P450 2E1 in alcohol and acetaminophen interactions. *Cells*. 2022;11(17):2620.
46. Chidiac AS, Buckley NA, Noghrehchi F, Cairns R. Paracetamol overdose and hepatotoxicity. *Expert Opin Drug Metab Toxicol*. 2023;19(5):297–317.
47. Bateman D, Dart R, Dear J, Prescott L, Rumack B. Fifty years of paracetamol poisoning. *Clin Toxicol (Phila)*. 2024;61:1–12.
48. Persson HE, Sjöberg GK, Haines JA, Pronczuk de Garbino J. Poisoning severity score. *J Toxicol Clin Toxicol*. 1998;36(3):205–213.
49. Schwarz ES, Kopec KT, Wiegand TJ, Wax PM, Brent J. Should we be using the poisoning severity score? *J Med Toxicol*.

2017;13:135–145.
50. Lopes RD, Horowitz JD, Garcia DA, Crowther MA, Hylek EM. Warfarin and acetaminophen interaction. *Blood*. 2011;118(24):6269–6273.
51. Abushanab D, Gasim M, Devi D, et al. Patterns and outcomes of paracetamol poisoning management in Qatar. *Medicine (Baltimore)*. 2023;102(38):e34872.
52. Abdel-Moez AM, Manal AA, Eman SM. Glutathione S-transferase (A1) as a marker of acute acetaminophen-induced hepatotoxicity. *Minia J Med Res*. 2020;31(3):240–251.
53. Li R, Liu F, Chang Y, et al. GSTA1 as a marker of acetaminophen-induced hepatocyte injury in vitro. *Toxicol Mech Methods*. 2017;27(6):401–407.
54. Khalaf MAM, Hefnawy AA, Abolhamd M. Serum cytokeratin 18-Asp396 as early predictor of acute paracetamol hepatotoxicity. *Ain Shams J Forensic Med Clin Toxicol*. 2016;27:27–36.
55. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. *J Lab Clin Med*. 1963;61(5):882–888.
56. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides by thiobarbituric acid reaction. *Anal Biochem*. 1979;95(2):351–358.
57. Vale JA, Meredith TJ, Goulding R. Treatment of acetaminophen poisoning: oral methionine. *Arch Intern Med*. 1981;141(3 Spec No):394–396.
58. Saljoughian M. Acetaminophen intoxication: A critical-care emergency. *US Pharm*. 2016;41(12):38–41.
59. Green JL, Heard KJ, Reynolds KM, Albert D. Oral and intravenous acetylcysteine for acetaminophen toxicity. *West J Emerg Med*. 2013;14(3):218–226.
60. Marks DJB, Dargan PI, Archer JRH, et al. Outcomes from massive paracetamol overdose. *Br J Clin Pharmacol*. 2017;83(6):1263–1272.
61. Ghannoum M, Kazim S, Grunbaum AM, Villeneuve E, Gosselin S. Massive acetaminophen overdose and hemodialysis. *Clin Toxicol (Phila)*. 2016;54(6):519–522.
62. Pourbagher-Shahri AM, Schimmel J, Shirazi FM, Nakhaee S, Mehrpour O. Use of fomepizole for acetaminophen poisoning: A scoping review. *Toxicol Lett*. 2022;355:47–61.
63. Dong V, Karvellas CJ. Liver assistive devices in acute liver failure. *Best Pract Res Clin Gastroenterol*. 2024;73:101964.
64. MacDonald AJ, Subramanian RM, Olson JC, et al. Molecular adsorbent recirculating system in acute liver failure. *Crit Care Med*. 2022;50(2):286–295.
65. Rahimi M, Shadnia S, Mostafazadeh B, et al. Acetaminophen poisoning: Case reports of early liver dialysis. *Clin Case Rep*. 2025;13(7):e70642.